IL0011809592
© PR Newswire
04.12.2025
NRSN
LISTED
NASDAQ
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
News Preview
CAMBRIDGE, Mass., Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a productive discussion with Health Canada ("Agency"), the Company is resuming its regulatory advanc...
Themefolio
Profiler
Peergroup
© PR Newswire
24.11.2025
NRSN
LISTED
NASDAQ
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
News Preview
CAMBRIDGE, Mass., Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational New Drug (IND) am...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
NRSN
LISTED
NASDAQ
NeuroSense to Host Investor Webinar on December 8, 2025
News Preview
Business, regulatory and clinical updates will be provided
CAMBRIDGE, Mass., Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenera...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
06.10.2025
NRSN
LISTED
NASDAQ
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
News Preview
CAMBRIDGE, Mass., Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced new positive findings based on plasma samples from its Phase-2b PARADIGM study....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
10.09.2025
NRSN
LISTED
NASDAQ
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
News Preview
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile
CAMBRIDGE, Mass., Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative disease...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2025
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
News Preview
Financing at 40% premium to market price provides near-term bridge to anticipated milestones
CAMBRIDGE, Mass., Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into...
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2025
NRSN
LISTED
NASDAQ
NeuroSense Provides Business Update and Progress for the First Half of 2025
News Preview
CAMBRIDGE, Mass., July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and financial results of the first half of 2025.
NeuroSense is...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
NRSN
LISTED
NASDAQ
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
News Preview
Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones & Go-to-Market Options in a Must-Watch Event
CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSens...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2025
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
News Preview
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity
CAMBRIDGE, Mass., May 7, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing nove...
Themefolio
Profiler
Peergroup
© PR Newswire
24.04.2025
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
News Preview
Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with global pharmaceutical company
CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-st...
Themefolio
Profiler
Peergroup
© PR Newswire
09.04.2025
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
News Preview
New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.
CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promi...
Themefolio
Profiler
Peergroup
© PR Newswire
07.04.2025
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
News Preview
Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional declineOngoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization Phase 3 study design for PrimeC in ALS aligned with FDA; planned initiation in 2025CAMBRIDGE, Mass., April 7,...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
04.04.2025
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
News Preview
Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense
CAMBRIDGE, Mass., April 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative disea...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
NRSN
LISTED
NASDAQ
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
News Preview
Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K filed with the SEC this morning, Health Canada has invited the company to a pre-New Drug Submission (pre-NDS) meeting to discuss a potential Notice of Compliance...
Themefolio
Profiler
Peergroup
© BusinessWire
17.03.2025
NRSN
LISTED
NASDAQ
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape
News Preview
PESG Research releases a new report covering NeuroSense Therapeutics (NASDAQ: NRSN)* and its recent developments: In a medical landscape hungry for innovation, NeuroSense Therapeutics (NASDAQ: NRSN) stands at the forefront of a potential revolution in ALS treatment, developing a groundbreaking combination therapy that could fundamentally transform...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
NRSN
LISTED
NASDAQ
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
News Preview
NeuroSense in Compliance with all Nasdaq Listing RequirementsCAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from...
Themefolio
Profiler
Peergroup
© PR Newswire
23.12.2024
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
News Preview
Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 studyAdditionally, milestone payments and double-digit royalties on annual net salesThe transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025CAMBRIDGE, Mass., Dec. 23, 2024 /PRNewswi...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
NRSN
LISTED
NASDAQ
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
News Preview
CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today provided business update with corporate highlights to date and third quarter financial results.
"The completion of the 18-...
Themefolio
Profiler
Peergroup
© PR Newswire
11.12.2024
NRSN
LISTED
NASDAQ
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
News Preview
The Type C meeting with the FDA, combined with the recent 18-month Phase 2b PARADIGM study readout, has the Company on track to commence a Phase 3 study in mid-2025PrimeC has already demonstrated a significant impact on slowing disease progression and increasing survival rates in people living with ALSCAMBRIDGE, Mass., Dec. 11, 2024 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
04.12.2024
NRSN
LISTED
NASDAQ
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
News Preview
In participants who received PrimeC from the start of the 18-month study compared to those initially on placebo before transitioning to PrimeC, disease progression was slowed by 33% (p=0.007), demonstrated in a 58% improvement in survival rates Consistent data across subgroups underscore the potential of PrimeC to redefine the standard of care in...
Themefolio
Profiler
Peergroup
© PR Newswire
02.12.2024
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
News Preview
CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the entry into a definitive agreement with a single investor and with NeuroSense's Chief Executive Officer, Mr. Al...
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2024
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
News Preview
CAMBRIDGE, Mass., Nov. 21, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, is pleased to announce its participation in the 2024 International Symposium on ALS/MND, to be held December 6-8, 2024, in Montre...
Themefolio
Profiler
Peergroup
© PR Newswire
28.10.2024
NRSN
LISTED
NASDAQ
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
News Preview
Meeting discussion to focus on finalizing Phase 3 study design and NDA readiness, ensuring a clear regulatory path for submission based on trial successParallel preparations in Canada: NeuroSense plans to submit its dossier in Q2 2025, with a regulatory decision on commercialization expected by Q1 2026CAMBRIDGE, Mass., Oct. 28, 2024 /PRNewswire/...
Themefolio
Profiler
Peergroup
© PR Newswire
24.10.2024
NRSN
LISTED
NASDAQ
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
News Preview
Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment
CAMBRIDGE, Mass., Oct. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced transformative findings from its PARADIGM clinica...
Themefolio
Profiler
Peergroup
© PR Newswire
15.10.2024
NRSN
LISTED
NASDAQ
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
News Preview
Dossier submission planned for Q2 2025; regulatory decision expected by Q1 2026 Estimated potential market opportunity: peak of $100M to $150M in annual revenueCompany aims to expand approval efforts to additional global marketsCAMBRIDGE, Mass., Oct. 15, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clini...
Themefolio
Profiler
Peergroup
© PR Newswire
09.10.2024
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
News Preview
The preparations for the regulatory submission for early commercialization in Canada follows the positive Phase 2b trial results which show PrimeC reduces ALS disease progression by 36% and improves survival rates by 43% Company plans to seek approval in additional countriesCAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics L...
Themefolio
Profiler
Peergroup
© PR Newswire
07.10.2024
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
News Preview
CAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced the acceptance of two abstracts focusing on the company's lead drug candidate, PrimeC, for the treatment of Amyotr...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2024
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
News Preview
The Company's intellectual property now covers the combination, formulation, and method of use of PrimeCPatent protection extends through 2042, adding four additional years to PrimeC's IP umbrellaCAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company...
Themefolio
Profiler
Peergroup
© PR Newswire
24.09.2024
NRSN
LISTED
NASDAQ
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
News Preview
CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid pric...
Themefolio
Profiler
Peergroup
© PR Newswire
30.08.2024
NRSN
LISTED
NASDAQ
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
News Preview
CAMBRIDGE, Mass., Aug. 30, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC ("Nasdaq"). The lett...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
